SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma
2011

House Dust Mite Immunotherapy for Asthma

Sample size: 54 publication 10 minutes Evidence: moderate

Author Information

Author(s): Blumberga G, Groes L, Dahl R

Primary Institution: Aarhus University Hospital

Hypothesis

The immunomodulatory ability of SQ-standardized house dust mite subcutaneous immunotherapy (SCIT) was investigated in patients with allergic asthma.

Conclusion

SQ-standardized HDM SCIT induced a consistent immunomodulatory effect in adults with HDM-allergic asthma, increasing HDM-allergen tolerance in the lungs and skin.

Supporting Evidence

  • The SCIT group showed a 1.6-fold increase in HDM-allergen tolerance compared to placebo.
  • Fewer patients in the SCIT group experienced late asthmatic reactions compared to the placebo group.
  • Skin test reactions were significantly reduced in the SCIT group after 3 years.

Takeaway

This study shows that a special treatment for asthma caused by dust mites can help people breathe better and reduce their allergy symptoms.

Methodology

54 adults with HDM-allergic asthma were randomized to receive either SQ-standardized HDM SCIT or placebo for 3 years, with various asthma control measures taken at baseline and after each year.

Potential Biases

Potential bias due to the double-blind design and the reliance on self-reported asthma control measures.

Limitations

The study had a relatively small sample size and was limited to a specific population of adults with HDM-allergic asthma.

Participant Demographics

54 adults aged 18–60, including 32 men and 22 women, all Caucasian.

Statistical Information

P-Value

0.028

Confidence Interval

(0.26; 0.37)

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1111/j.1398-9995.2010.02451.x

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication